Tenon Medical, INC Form 4 insider transactions

Tenon Medical's Chief Commercial Officer, Nathaniel A. Grawey, increased his direct and indirect beneficial ownership through a private investment in public equity transaction.

Tenon Medical, Inc. CEO and President Steven M. Foster was granted 281,872 restricted stock units, vesting in two tranches in 2026.

Tenon Medical Director Stephen Hochschuler was granted 21,464 restricted stock units, vesting in two tranches in 2026.

Tenon Medical, Inc. Director Robert K. Weigle was granted 21,464 restricted stock units, vesting in two tranches in 2026.

Tenon Medical's Chief Technology Officer, Richard Ginn, was granted 253,153 restricted stock units, aligning his interests with future company performance.

Tenon Medical, Inc. Director Richard Ferrari was granted 128,957 restricted stock units, vesting in two tranches in 2026.

Tenon Medical, Inc. Director Kristine M. Jacques received a grant of 20,293 restricted stock units, which will vest in two equal tranches in 2026.

Tenon Medical's Chief Financial Officer and Director, Kevin Williamson, was granted 117,974 restricted stock units, vesting in two tranches in 2026.

Tenon Medical, Inc. Director Ivan Howard was granted 21,464 restricted stock units, aligning his interests with shareholders.